Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers
Yoon Young ChoiiD, Su‐Jin ShiniD, Jae Eun LeeiD, Lisa MadlenskyiD, Seung‐Tae LeeiD, Ji Soo ParkiD, Jeong-Hyeon Jo, Hyunki KimiD, Daniela NachmansoniD, Xiaojun XuiD, Sung Hoon NohiD, Jae‐Ho CheongiD, Olivier HarismendyiD
Abstract
BackgroundAlong with early onset cancers, multiple primary cancers (MPCs) are likely resulting from increased genetic susceptibility; however, the associated predisposition genes or prevalence of the pathogenic variants genes in MPC patients are often unknown. MethodsWe screened 71 patients with MPC of the stomach, colorectal, and endometrium, sequencing 65 cancer predisposition genes. A subset of 19 patients with early onset MPC of stomach and colorectum were further evaluated for at DNA repair and cancer related genes using both normal (germline) and tumor (somatic) whole exome sequencing. ResultsAmong 71 patients with MPCs, variants predicted to be pathogenic were observed in 15 (21.1%) patients and affected Lynch Syndrome (LS) genes: MLH1 (n=10), MSH6 (n=2), PMS2 (n=2), and MSH2 (n=1). All carriers had tumors with high microsatellite instability and 13 of them (86.7%) were early-onset, consistent with LS. In 19 patients with early-onset MPCs, loss of function (LoF) variants in RECQL5, including a rare East-Asian specific variant, were more prevalent in non-LS MPC than in matched sporadic cancer patients (OR=31.6, p=0.001). Additional evaluation of bi-allelic alterations in the tumor correctly identified LS genes in LS patients and candidates genes in non-LS patients including high-confidence LoF variants in 2 patients, FANCG (c.307+1G>C) and CASP8 (p.R221Sfs*17) both accompanied by somatic loss of heterozygosity in a gastric and a colorectal tumor, respectively. ConclusionsThe results suggest that genetic screening should be considered for synchronous cancers and metachronous MPCs of the LS tumor spectrum, particularly in early-onset patients. Susceptibility variants in non-LS genes for MPC patients may exist, but evidence for their role is more elusive than for LS patients.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 1.17
- Field percentile
- top 23%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cancer risks for MSH6 pathogenic variant carriers
A.S. van der Werf – ‘t Lam, James G. Dowty, … Maartje Nielsen·medRxiv·Feb 15, 2025
- Lynch syndrome in the general population: low clinical utility of genomic screening for PMS2 pathogenic variants
Kelly M. Schiabor Barrett, Catherine A. Hajek, … Alexandre Bolze·medRxiv·Feb 3, 2025
- Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank
Eilidh Fummey, Pau Navarro, … Albert Tenesa·Journal of Medical GeneticsPeer-reviewed·Jul 14, 2024
- A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome
Romy Walker, Khalid Mahmood, … Daniel D. Buchanan·Journal of Translational MedicinePeer-reviewed·Apr 26, 2023
- Germline and Tumor Whole Genome Sequencing as a Diagnostic Tool to Resolve Suspected Lynch Syndrome
Bernard J. Pope, Mark Clendenning, … Daniel D. Buchanan·Journal of Molecular DiagnosticsPeer-reviewed·Dec 28, 2020
- Saturation-scale functional evidence supports clinical variant interpretation in Lynch Syndrome
Anthony J. Scott, Felicia Hernandez, … Jacob Otto Kitzman·Genome biologyPeer-reviewed·Dec 22, 2022